Sunshine Heart Welcomes Dr. Patrick Verta as Chief Medical Officer

Sunshine Heart Welcomes Dr. Patrick Verta as Chief Medical Officer

EDEN PRAIRIE, Minn., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc.
(Nasdaq:SSH) announced that, effective today, Patrick Verta, MD, has joined
the Company as Chief Medical Officer. Dr. Verta brings over 20 years of
experience in the medical fieldwith the majority of time spent in the
cardiovascular field.

Prior to joining Sunshine Heart, Dr. Verta served as Chief Medical Officer and
Vice President of Clinical Affairs at Neomend, a medical device company that
developed and commercialized the only FDA-approved sealant for air leaks
following lung surgery via open thoracotomy. The company was acquired by
Bard/Davol in October 2012. Before Neomend, he served as Medical Director of
Clinical Research and Business Development at Abbott Vascular, where he played
a critical role in the approval of several stent systems used in peripheral
vascular disease, in particular carotid artery stenosis, renal artery
stenosis, and peripheral Artery Disease (PAD).While at Abbott, Dr. Verta led
the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST),
the largest randomized carotid trial ever, enrolling over 2,500 patients and
considered today to be the gold standard for carotid stenting trials. Prior to
Abbott, Dr. Verta held the position of Endovascular Clinical Science and
Biometrics Director at Guidant Corporation.

In addition to his experience driving clinical trials, he has co-authored
seventeen manuscripts on novel medical device therapies in peer-review
journals, and is credited with two patents in the data management and
electronic data capture areas. Dr. Verta holds a Doctorate of Medicine from
the Faculté de Médecine in Paris, France; as well as a Doctorate of Veterinary
Medicine from the Ecole Nationale Vétérinaire d'Alfort, France. He also
completed a Masters Degree in Biostatistics at the University of Paris.

"We are pleased and fortunate to welcome Dr. Verta to Sunshine Heart as Chief
Medical Officer," said Dave Rosa, Sunshine Heart's CEO. "His experience
conducting large, complex clinical trials will be essential as we continue to
progress within both our U.S. pivotal trial, COUNTER HF; as well as our
European post-market study, OPTIONS HF. In particular, we look forward to his
contributions toward accelerating and managing prudent site selection and
enrollment with regard to both clinical trials going forward." 

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device
in the United States, Canada and countries that do not recognize the CE mark
approval, utilizes the scientific principles of intra-aortic balloon
counterpulsation applied in an extra-aortic approach to assist the left
ventricle by reducing the workload required to pump blood throughout the body,
while increasing blood flow to the coronary arteries.Combined, these
potential benefits may help sustain the patient's current condition or, in
some cases, reverse the heart failure process, thereby potentially preventing
the need for later-stage heart failure devices, such as left ventricular
assist devices (LVADs), artificial hearts or transplants. It may also provide
relief from the symptoms of Class III and ambulatory Class IV heart failure
and improve quality of life and cardiac function. Based on the results from
our feasibility trial, we also believe that some patients treated with our
C-Pulse System will be able to stop using the device due to sustained
improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to
Investigational use.

About Sunshine^® Heart

Sunshine Heart,Inc. (Nasdaq:SSH) is a medical device company focused on
developing, manufacturing and commercializing the C-Pulse System for treatment
of Class III and ambulatory Class IV heart failure. Sunshine Heart has
completed an approved U.S. Food and Drug Administration (FDA) feasibility
clinical trial of the C-Pulse System and presented the results in
November2011. In March 2012, the FDA notified the Company that it could move
forward with an investigational device exemption (IDE) application. Sunshine
Heart received unconditional approval from the FDA in November2012 to
initiate its pivotal trial. In July2012 Sunshine Heart received CE Mark
approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware
corporation headquartered in Minneapolis with a wholly owned subsidiary in
Australia. The Company has been listed on the NASDAQ Capital Market since
February2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are
based on management's beliefs, assumptions, expectations, and information
currently available to management. All statements that address future
operating performance, events or developments that we expect or anticipate
will occur in the future are forward-looking statements, including, without
limitation, future clinical trial activities and results including patient
enrollment in trials. These forward-looking statements are subject to numerous
risks and uncertainties, including, without limitation, the possibility that
our clinical trials do not meet their enrollment goals, meet their endpoints
or otherwise fail, that regulatory authorities do not accept our application
or approve the marketing of the C-Pulse System, the possibility that we may be
unable to raise the funds necessary for the development and commercialization
of our products, that we may not be able to commercialize our products
successfully in the EU and the other risk factors described under the caption
"Risk Factors" and elsewhere in our filings with the SEC. You should not
place undue reliance on forward-looking statements because they speak only as
of the date when made and may turn out to be inaccurate. We do not assume any
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. We may not
actually achieve the plans, projections or expectations disclosed in
forward-looking statements, and actual results, developments or events could
differ materially from those disclosed in the forward-looking statements.

CONTACT: Media:
         Laura Forman
         Blueprint Life Science Group
         T: +1-415-375-3340
        
         Investor:
         Jeff Mathiesen
         Chief Financial Officer
         Sunshine Heart, Inc.
         T: +1-952-345-4200

Sunshine Heart logo
 
Press spacebar to pause and continue. Press esc to stop.